Onderneming PHAXIAM Therapeutics S.A. Deutsche Boerse AG
Aandelen
2E40
FR001400K4B1
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,95 EUR | +3,17% |
|
-1,02% | -56,18% |
12/06 | Phaxiam: kapitaalverhoging van tien miljoen euro | CF |
15/04 | Phaxiam start studie in infectieuze endocarditis | CF |
Vakgebied
Aantal werknemers: 68
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-23 |
Cindy Fevre
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-23 |
Céline Breda
CTO | Chief Tech/Sci/R&D Officer | 54 | 23-06-23 |
Karine Charton
PRN | Corporate Officer/Principal | - | 23-06-23 |
General Counsel | - | 23-06-23 | |
Human Resources Officer | - | 23-06-23 | |
Jérôme Bailly
PRN | Corporate Officer/Principal | 45 | 23-06-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 23-06-23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-23 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-23 |
Martine George
BRD | Director/Board Member | 76 | 23-06-23 |
Director/Board Member | 66 | 23-06-23 | |
Didier Hoch
CHM | Chairman | 68 | 23-06-23 |
Leila Nicolas
BRD | Director/Board Member | - | 23-06-23 |
Robert Sebbag
BRD | Director/Board Member | 73 | 23-06-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 11 137 712 | 10 660 161 ( 95,71 %) | 270 ( 0,002429 %) | 95,71 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
250 | 0.00% | 813 $ |
Bedrijfsgegevens
![Adres PHAXIAM Therapeutics S.A.(2E40)](https://cdn.zonebourse.com/static/address/159414587.png)
Sector
Verkoop per regio
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,20% | 121 mld. | |
+19,67% | 113 mld. | |
+17,15% | 26,02 mld. | |
-23,86% | 19,39 mld. | |
-19,61% | 15,91 mld. | |
-20,90% | 15,09 mld. | |
-46,14% | 15,06 mld. | |
+63,85% | 14,93 mld. | |
+4,49% | 13,85 mld. |
- Beurs
- Aandelen
- Koers PHXM
- Koers 2E40
- Onderneming PHAXIAM Therapeutics S.A.